Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01137786 · ClinicalTrials.gov registry record · Phase 4

Kidney Damage in Patients With Normal eGFR

A Phase 4 study of Coronary Artery Stenosis, sponsored by Bracco Diagnostics.

Completed
Registry status
Phase 4
Development phase
49
Enrollment target
1
Study location

NCT01137786: Completed Phase 4 study of Coronary Artery Stenosis, sponsored by Bracco Diagnostics.

NCT01137786 is a Phase 4 study of Coronary Artery Stenosis that has completed, run by Bracco Diagnostics. The registered enrollment target is 49 participants, below the 1,654-participant average among 4 other Coronary Artery Stenosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01137786, a Phase 4 study of Coronary Artery Stenosis, has completed, sponsored by Bracco Diagnostics.

COMPLETED
Registry status
Phase 4
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.

Primary Outcome

Mean change from baseline values for serum NGAL at 2,4,6,24,48 and 72 hours, and urine NGAL at 2,4,6,24, and 48 hours following the administration of non-ionic low osmolar contrast media.

Conditions Studied

Interventions

  • DRUG Non ionic contrast media comparator

Study Locations (1)

Illinois

  • Prairie Cardiovascular Consultants, Ltd. - Springfield

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2010-12
Est. Completion 2012-04
Phase Phase 4
Bracco Diagnostics

37 total trials

What the finished NCT01137786 record still lists

NCT01137786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,654-participant average among 4 other Coronary Artery Stenosis trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Coronary Artery Stenosis appearing as the primary indexed condition, and to 1 intervention - of which Non ionic contrast media comparator is the first listed.

NCT01137786 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT01137786 about?

NCT01137786 is a clinical study titled "Kidney Damage in Patients With Normal eGFR". This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two g...

What is the current status of trial NCT01137786?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2010-12. Estimated completion is 2012-04.

What conditions does trial NCT01137786 study?

This clinical trial studies the following conditions: Coronary Artery Stenosis.

What interventions are being tested in trial NCT01137786?

The interventions under investigation include: Non ionic contrast media comparator (DRUG).

Who is sponsoring clinical trial NCT01137786?

This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01137786 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Stenosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02704858 · 49 participants · Phase 1

    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

  • NCT03516708 · 49 participants · Phase 1

    Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

  • NCT03692429 · 49 participants · Phase 1

    alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

  • NCT04329494 · 49 participants · Phase 1

    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01137786, the US trial registry maintained by the National Library of Medicine. NCT01137786 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.